<?xml version="1.0" encoding="UTF-8"?>
<p>A basic rule to be followed, based on the much-needed protection of patients, is then to address differences on the basis of their inherent complexity of structures and delivery systems, without any oversimplification that could compromise both safety or efficacy. This major concern has been correctly addressed when developing the biosimilars pathway since 2004 (
 <xref rid="B15" ref-type="bibr">15</xref>), but does not completely address the main issues related to NBCDs.
</p>
